1408pthe United Kingdom (uk) National Cancer Research Network (ncrn) Chemotherapy and Pharmacy Advisory Service (cpas): Service Development and Quality Control Experience of Pharmacy Aspects in Clinical Research Protocols.

P.R. Debruyne1, P. Johnson2, L. Pottel1, S. Daniels3, R. Greer4, E. Hodgkinson5, S. Kelly6, M. Lycke1, J. Samol7, J. Simpson8, D. Kimber9, E. Loucaides10, M. K. Parmar11, S. Harvey12 Campus Loofstraat Cancer Center, General Hospital Groeninge, Kortrijk, BELGIUM Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK Pharmacy Cancer Services, University College London Hospitals, London, UK Clinical Pharmacology, Leeds Teaching Hospital NHS Trust, Leeds, UK Clinical Pharmacology, 6Sheffield Teaching Hospitals NHS Foundation Trust, Scheffield, UK Dept. Oncology Uk, Pfizer Ltd., Tadworth, UK Medical Oncology, St George’s Hospital, London, UK Clinical Pharmacology, Sandwell and West Birmingham Hospitals NHS Trust, West Midlands, UK Wessex Clinical Senate & Strategic Networks, NHS England, Southampton, UK NCRI Clinical Studies Groups, London, UK Medical Research Council (mrc)mrc Clinical Trials Unit, University College London, London, UK NCRN CPAS, National Cancer Research Network Coordinating Centre, London, UK Aim: The Chemotherapy and Pharmacy Advisory Service (CPAS) was established in 2007 by the UK National Cancer Research Network (NCRN) to improve the quality of pharmacy-related issues in clinical research protocols. We report the scope and methodology of the CPAS, and its impact on the quality of clinical research protocols.